ABIN738156
antibody from antibodies-online
Targeting: RUNX2
AML3, CBFA1, CCD, CCD1, PEBP2A1, PEBP2aA1
Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN738156 - Provider product page
- Provider
- antibodies-online
- Proper citation
- Antibodies-Online Cat#ABIN738156, RRID:AB_11208809
- Product name
- anti-Runx1 + Runx2 (AA 200-250) antibody
- Antibody type
- Polyclonal
- Description
- Purified by Protein A.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Epitope
- AA 200-250
- Isotype
- IgG
- Vial size
- 100 μL
- Storage
- Store at -20°C
Submitted references Blockade of hypoxia-induced CXCR4 with AMD3100 inhibits production of OA-associated catabolic mediators IL-1β and MMP-13.
High expression of periostin is dramatically associated with metastatic potential and poor prognosis of patients with osteosarcoma.
Expression pattern of embryonic stem cell markers in DFAT cells and ADSCs.
Contribution of SATB2 to the stronger osteogenic potential of bone marrow stromal cells from craniofacial bones.
Li P, Deng J, Wei X, Jayasuriya CT, Zhou J, Chen Q, Zhang J, Wei L, Wei F
Molecular medicine reports 2016 Aug;14(2):1475-82
Molecular medicine reports 2016 Aug;14(2):1475-82
High expression of periostin is dramatically associated with metastatic potential and poor prognosis of patients with osteosarcoma.
Hu F, Wang W, Zhou HC, Shang XF
World journal of surgical oncology 2014 Sep 15;12:287
World journal of surgical oncology 2014 Sep 15;12:287
Expression pattern of embryonic stem cell markers in DFAT cells and ADSCs.
Gao Q, Zhao L, Song Z, Yang G
Molecular biology reports 2012 May;39(5):5791-804
Molecular biology reports 2012 May;39(5):5791-804
Contribution of SATB2 to the stronger osteogenic potential of bone marrow stromal cells from craniofacial bones.
Zhang P, Men J, Fu Y, Shan T, Ye J, Wu Y, Tao Z, Liu L, Jiang H
Cell and tissue research 2012 Dec;350(3):425-37
Cell and tissue research 2012 Dec;350(3):425-37
No comments: Submit comment
No validations: Submit validation data